Equity Overview
Price & Market Data
Price: $0.314
Daily Change: -$0.0072 / 2.29%
Daily Range: $0.305 - $0.337
Market Cap: $11,174,612
Daily Volume: 752,159
Performance Metrics
1 Week: -8.58%
1 Month: -32.62%
3 Months: -64.97%
6 Months: -71.56%
1 Year: -85.17%
YTD: -84.02%
Company Details
Employees: 19
Sector: Health technology
Industry: Medical specialties
Country:
Details
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.